{
    "root": "e352999f-5bf1-4ac6-ab65-f6ecd1d40a83",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Levetiracetam",
    "value": "20250515",
    "ingredients": [
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POLYVINYL ALCOHOL",
            "code": "532B59J990"
        },
        {
            "name": "CI 77891",
            "code": "15FIX9V2JP"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P"
        },
        {
            "name": "CI 77492",
            "code": "EX438O2MRT"
        },
        {
            "name": "SILICA",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "LEVETIRACETAM",
            "code": "44YRR34555"
        }
    ],
    "indications": "levetiracetam tablets indicated treatment partial-onset seizures patients 1 month age older ( 1.1 ) levetiracetam tablets indicated adjunctive therapy treatment : • myoclonic seizures patients 12 years age older juvenile myoclonic epilepsy ( 1.2 ) • primary generalized tonic-clonic seizures patients 6 years age older idiopathic generalized epilepsy ( 1.3 )",
    "contraindications": "• oral solution pediatric patients body weight ≤ 20 kg ( 2.1 ) • pediatric patients , weight-based dosing oral solution calibrated measuring device ( household teaspoon tablespoon ) ( 2.1 ) partial-onset seizures ( monotherapy adjunctive therapy ) • 1 month < 6 months : 7 mg/kg twice daily ; increase 7 mg/kg twice daily every 2 weeks recommended dose 21 mg/kg twice daily ( 2.2 ) • 6 months < 4 years : 10 mg/kg twice daily ; increase 10 mg/kg twice daily every 2 weeks recommended dose 25 mg/kg twice daily ( 2.2 ) • 4 years < 16 years : 10 mg/kg twice daily ; increase 10 mg/kg twice daily every 2 weeks recommended dose 30 mg/kg twice daily ( 2.2 ) • adults 16 years older : 500 mg twice daily ; increase 500 mg twice daily every 2 weeks recommended dose 1500 mg twice daily ( 2.2 ) myoclonic seizures adults pediatric patients 12 years older • 500 mg twice daily ; increase 500 mg twice daily every 2 weeks recommended dose 1500 mg twice daily ( 2.3 ) primary generalized tonic-clonic seizures • 6 years < 16 years : 10 mg/kg twice daily , increase increments 10 mg/kg twice daily every 2 weeks recommended dose 30 mg/kg twice daily ( 2.4 ) • adults 16 years older : 500 mg twice daily , increase 500 mg twice daily every 2 weeks recommended dose 1500 mg twice daily ( 2.4 ) adult patients impaired renal function • dose adjustment recommended , based patient ’ estimated creatinine clearance ( 2.5 , 8.6 )",
    "warningsAndPrecautions": "product : 50090-1333 ndc : 50090-1333-0 120 tablet , film coated bottle ndc : 50090-1333-2 90 tablet , film coated bottle ndc : 50090-1333-1 60 tablet , film coated bottle ndc : 50090-1333-3 180 tablet , film coated bottle product : 50090-2875",
    "adverseReactions": "levetiracetam tablets contraindicated patients hypersensitivity levetiracetam . included anaphylaxis angioedema [ ( 5.4 ) ] .",
    "indications_original": "Levetiracetam tablets are indicated for the treatment of partial-onset seizures in patients 1 month of age and older ( 1.1 ) Levetiracetam tablets are indicated for adjunctive therapy for the treatment of: • Myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy ( 1.2 ) • Primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy ( 1.3 )",
    "contraindications_original": "• Use the oral solution for pediatric patients with body weight ≤ 20 kg ( 2.1 ) • For pediatric patients, use weight-based dosing for the oral solution with a calibrated measuring device (not a household teaspoon or tablespoon) ( 2.1 ) Partial-Onset Seizures (monotherapy or adjunctive therapy) • 1 Month to < 6 Months: 7 mg/kg twice daily; increase by 7 mg/kg twice daily every 2 weeks to recommended dose of 21 mg/kg twice daily ( 2.2 ) • 6 Months to < 4 Years: 10 mg/kg twice daily; increase by 10 mg/kg twice daily every 2 weeks to recommended dose of 25 mg/kg twice daily ( 2.2 ) • 4 Years to < 16 Years: 10 mg/kg twice daily; increase by 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily ( 2.2 ) • Adults 16 Years and Older: 500 mg twice daily; increase by  500 mg twice daily every 2 weeks to a recommended dose of 1500 mg twice daily ( 2.2 ) Myoclonic Seizures in Adults and Pediatric Patients 12 Years and Older • 500 mg twice daily; increase by 500 mg twice daily every 2 weeks to recommended dose of 1500 mg twice daily ( 2.3 ) Primary Generalized Tonic-Clonic Seizures • 6 Years to < 16 Years: 10 mg/kg twice daily, increase in increments of 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily ( 2.4 ) • Adults 16 Years and Older: 500 mg twice daily, increase by 500 mg twice daily every 2 weeks to recommended dose of 1500 mg twice daily ( 2.4 ) Adult Patients with Impaired Renal Function • Dose adjustment is recommended, based on the patient’s estimated creatinine clearance ( 2.5 , 8.6 )",
    "warningsAndPrecautions_original": "Product:    50090-1333\n                  NDC:    50090-1333-0   120 TABLET, FILM COATED in a BOTTLE\n                  NDC:    50090-1333-2   90 TABLET, FILM COATED in a BOTTLE\n                  NDC:    50090-1333-1   60 TABLET, FILM COATED in a BOTTLE\n                  NDC:    50090-1333-3   180 TABLET, FILM COATED in a BOTTLE\n                  Product:    50090-2875",
    "adverseReactions_original": "Levetiracetam tablets are contraindicated in patients with a hypersensitivity to levetiracetam. Reactions have included anaphylaxis and angioedema\n \n  [see Warnings and Precautions (\n  \n   5.4)]\n \n  ."
}